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Two common disorders of the elderly are heart failure and Alzheimer disease (AD). Heart failure usually results from
dilated cardiomyopathy (DCM). DCM of unknown cause in families has recently been shown to result from genetic
disease, highlighting newly discovered disease mechanisms. AD is the most frequent neurodegenerative disease of older
Americans. Familial AD is caused most commonly by presenilin 1 (PSEN1) or presenilin 2 (PSEN2) mutations, a discovery
that has greatly advanced the ﬁeld. The presenilins are also expressed in the heart and are critical to cardiac development.
We hypothesized that mutations in presenilins may also be associated with DCM and that their discovery could provide
new insight into the pathogenesis of DCM and heart failure. A total of 315 index patients with DCM were evaluated
for sequence variation in PSEN1 and PSEN2. Families positive for mutations underwent additional clinical, genetic, and
functional studies. A novel PSEN1 missense mutation (Asp333Gly) was identiﬁed in one family, and a single PSEN2
missense mutation (Ser130Leu) was found in two other families. Both mutations segregated with DCM and heart failure.
The PSEN1 mutation was associated with complete penetrance and progressive disease that resulted in the necessity of
cardiac transplantation or in death. The PSEN2 mutation showed partial penetrance, milder disease, and a more favorable
prognosis. Calcium signaling was altered in cultured skin ﬁbroblasts from PSEN1 and PSEN2 mutation carriers. These
data indicate that PSEN1 and PSEN2mutations are associated with DCMand heart failure and implicate novelmechanisms
of myocardial disease.
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A great deal of effort has been expended to understand
mechanisms of degenerative disease. Two common dis-
eases—heart failure1 and Alzheimer disease2 (AD [MIM
104300])—increase dramatically in likelihood with age
and cause considerable morbidity and mortality. Identi-
ﬁcation of the genes that cause early-onset familial ADhas
greatly facilitated the understanding of potential disease
mechanisms for patients, of all ages, with AD. Since the
discovery of the presenilin 1 gene (PSEN1 [MIM 104311])
in 1995,3 1100 mutations have been reported in cases
of early-onset familial AD.4 Presenilin 2 (PSEN2 [MIM
600759]),5 highly homologous to PSEN1, is a less common
cause of familial AD.6 It has been suggested that amyloid
ﬁbril accumulation is in part responsible for the neuro-
degeneration observed in AD.7–10 Other postulated disease
mechanisms include apoptosis, aberrant calcium signal-
ing, or other disordered intracellular signaling, such as the
b-catenin/Wnt pathway.7–10 Recent studies have focused
on genetic variation that increases the risk of AD.11 Ini-
tially thought to be a rare, noninherited cause of demen-
tia, AD is now recognized as a common disease with im-
portant underlying genetic factors.12
Dilated cardiomyopathy (DCM [MIM115200]) resulting
from any cause, including ischemic disease, is the most
common antecedent to heart failure.1 DCM of unknown
etiology after exclusion of ischemic cardiomyopathy and
all other known causes is termed “idiopathic dilated car-
diomyopathy” (IDC). IDC has been shown to occur as
familial DCM (FDC) in 20%–50% of cases,13 implicating
genetic causation. Since 1998, mutations in 115 genes
have been shown to cause autosomal dominant FDC13,14;
they account for approximately one-quarter of all cases13
and encode proteins essential either to the contractile ap-
paratus or cytoskeleton,13,14 to calcium handling,15 or to
potassium16 or sodium17 channels. A notable exception is
the pleiotropic lamin A/C, a component of the inner nu-
clear membrane, mutations of which cause DCM, con-
duction system disease, and several other disorders.13,18 To
date, there is no unifying hypothesis of DCM that inte-
grates these disparate genetic pathways.
Regardless of the initiating insult, DCM resembles a pro-
gressive, degenerative disease of the myocardium. Nota-
bly, the AD genes PSEN1 and PSEN2 are expressed in the
heart,19,20 and gene targeting in murine models has shown
the genes’ importance in cardiac development.21,22 Given
the possibility that mutations in these genes cause myo-
cardial disease, we screened the DNA specimens from our
cohort of 132 FDC-affected families and 183 subjects with
IDC or possible FDC23 for sequence variations in the cod-
ing exons of the PSEN1 and PSEN2 genes. We identiﬁed a
Figure 1. Presenilin sequencing electropherograms, sequence alignments, and protein structure, with known mutations and components
of the g-secretase complex. A, DNA-sequencing electropherograms for PSEN1 and PSEN2. The sequencing electropherogram for family
A demonstrated heterozygosity in PSEN1 at nucleotide 1539, which changed the wild-type aspartic acid to glycine. For families B and
C, heterozygosity was demonstrated in PSEN2 at nucleotide 756, which changed the wild-type serine to a leucine. B, PSEN1 and PSEN2
sequence alignments. The amino acid sequences of PSEN1 and PSEN2 from various species are shown and indicate that the mutations
occurred in highly conserved residues. C, Presenilin 1 protein structure and mutation locations and the g-secretase complex. The putative
transmembrane structure of the 467-aa presenilin 1 protein is shown, including known AD mutations4,7,8 denoted by the crossed symbols.
Most AD mutations reside in the transmembrane domains,4 whereas the DCM mutation (solid symbol with arrow) identiﬁed in family A
resides in the large, intracytoplasmic loop. The proposed topology of the 448-aa presenilin 2 protein (not shown) closely resembles
that of presenilin 1. The PSEN2 mutation identiﬁed in families B and C resides at position 130 in its ﬁrst extracellular domain, near a
previously reported AD mutation at aa 122,26 which is also in the ﬁrst extracellular domain. PSEN1 is shown accompanied by APH-1,
nicastrin, and PEN2, proteins that constitute the g-secretase complex and are required for g-secretase activity.9,20 Notch is shown as
a representative member of the type I membrane protein family. Notch, following extracellular binding of its ligands Delta or Jagged,
undergoes presenilin-mediated g-secretase cleavage, which generates its active, intracellular signaling domain that translocates to the
nucleus and acts as a transcriptional regulator in diverse systems, including cardiovascular development and disease. APP27 and several
other transmembrane protein substrates, including Erb-B4 and E- and N-cadherins, are similarly processed.10
Table 1. Clinical Characteristics of Family Members with Presenilin Mutations
Family and Subject
Agea
(years) ECG Abnormalities DCM Comments
A:
II.3 51 Left bundle branch block Yes Ejection fraction 23%; LV dimension, in diastole, of 66 mm by echocardiography; negative coro-
nary angiography; heart transplant at age 62 years; death related to transplant complications
II.4 52 First-degree atrioventricular block; LV hypertrophy Yes Ejection fraction 15%; LV dimension, in diastole, of 66 mm by echocardiography; negative
coronary angiography; implantable cardiac deﬁbrillator for syncope at age 55 years; stable on
medical therapy at age 61 years
III.3 39 LV hypertrophy Yes Ejection fraction 10%; LV dimension, in diastole, of 77 mm; progressive heart failure until death
at age 44 years
B:
II.3 80 No records No records Dementia onset at age 75 years; death from progressive dementia at age 80 years
II.5 62 No records No records Died in 7th decade after history of multiple episodes of syncope; no medical records available
III.2 54 No No Normal cardiovascular screening
III.3 50 Anteroseptal infarct pattern No Negative stress echocardiography for ischemia
III.5 55 First-degree atrioventricular block; atrial ﬁbrillation;
LV hypertrophy
Yes Presented in heart failure; ejection fraction 10%; LV dimension, in diastole, of 60 mm; negative
coronary angiography
III.7 55 Anterior infarct pattern; nonspeciﬁc ST-T changes No LV dimension, in diastole, of 56 mm (199th percentile), with normal systolic function; ejection
fraction estimated at 60%; negative coronary angiography; no heart failure
III.8 48 Anterior infarct pattern; nonspeciﬁc ST-T changes Yes Initial ejection fraction 38%; negative coronary angiography; heart failure
3 years later; ejection fraction 24%; LV dimension, in diastole, of 80 mm
III.9 50 Anterior infarct pattern; nonspeciﬁc ST-T changes No Negative stress echocardiography for ischemia
C:
I.1 72 No No Poor echocardiographic window, but probably within normal limits; no heart failure
II.2 45 No Yes LV dimension, in diastole, of 53 mm (97.5 percentile); ejection fraction estimated at 40%, with
diffuse global hypokinesis; no heart failure
II.4 44 No No Data from outside medical records; no cardiovascular abnormalities observed; no heart failure
II.5 36 Anterior infarct pattern; nonspeciﬁc ST-T changes Yes Presented in heart failure; ejection fraction 23%; LV dimension, in diastole, of 73 mm; negative
coronary angiography; progressive heart failure stabilized with full medical therapy at age 45
years
II.7 40 Nonspeciﬁc ST-T changes Yes Ejection fraction 35%; LV dimension, in diastole, of 59 mm (199th percentile); negative coronary
angiography; no heart failure; LV function improved with medical therapy
III.2, 3, 4, 8, and 9 !35 No No
a Age at diagnosis of cardiovascular disease or age at cardiovascular screening.
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Figure 2. Pedigrees of families A, B, and C with presenilin mutations. Diamonds represent either males or females. Symbols with a
diagonal line represent deceased family members. Black symbols indicate family members affected with DCM with or without heart
failure, half–ﬁlled symbols represent those with abnormal ECGs, gray symbols represent family members who were of unknown status,
and white symbols represent family members who were unaffected. The presence () or absence () of PSEN1 (family A) or PSEN2
(families B and C) mutations are indicated for those from whom DNA was available. For family B, a plus sign within parentheses ()
indicates obligate carriers of the PSEN2 mutation.
novel PSEN1 mutation in one family and a single PSEN2
missense mutation in two other families. In all three cases,
the mutations were present in all clinically affected sub-
jects and segregated with DCM and heart failure.
Material and Methods
Clinical Evaluation
Written, informed consent was obtained from all subjects, and
the Oregon Health & Science University (OHSU) Institutional Re-
view Board approved the study. Clinical data for the 315probands
were obtained through our own evaluations, as described else-
where,23,24 or throughmedical-record or death-certiﬁcatereview.23,24
IDCwas deﬁned by left ventricular (LV) enlargement—withsystolic
dysfunction (ejection fraction 0.50)—and the exclusion of other
causes of cardiomyopathy. FDC was deﬁned by a documented di-
agnosis of IDC in two or more family members. The genotyped
members of the three families presented here were evaluated by us
(history, exam, electrocardiogram [ECG], and echocardiogram).
Genetic Studies
DNA was prepared from fresh whole blood. The human PSEN1
spans 183 kb and comprises 11 protein-coding exons. The hu-
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man PSEN2 is 124 kb and also consists of 11 coding exons. PCR
was used to amplify each coding exon of both genes, as well as
of the following known DCM-causative genes encoding lamin
A/C (LMNA [MIM 150330]), b-myosin heavy chain (MYH7 [MIM
160760]), troponin T (TNNT2 [MIM 191045]), the cardiac sodium
channel (SCN5A [MIM 600163]), the muscle LIM domain pro-
tein (CSRP3 [MIM 600824]), and phospholamban (PLN [MIM
172405]). PCR products were sequenced in the forward and re-
verse directions (primer sequences and PCR conditions are avail-
able at the OHSU Familial Dilated Cardiomyopathy Research Pro-
ject Web site). DNA samples, used as unaffected controls with no
cardiovascular or neurological disease, totaled 413 and included
207 African American individuals. Haplotypes were constructed
for families B and C from genotypes of nine markers (D1S237–
D1S2785) ﬂanking the PSEN2 locus.
Tissue Studies
All tissues were ﬁxed in formalin, were embedded in parafﬁn, and
were stained by routine histological procedures. Immunoperox-
idase studies were performed using the Vector ABC horseradish
peroxidase kit with use of primary antibodies against the follow-
ing: amyloid-b peptide (4G8 [Signet], 1:1,000), hyperphosphor-
ylated tau (Tau-2 [Sigma], 1:1,000), a-synuclein (Ab [Novocastra],
1:500), and oligomerized protein (A11 [Biosource], 1:500). Sec-
tions from patients with AD, Lewy body disease, or amyloido-
genic cardiomyopathywere obtained from theOregonBrainBank
and were used as positive controls.
Fibroblast Calcium Studies
Measurement of [Ca2]i was performed using ﬂuorescence mi-
croscopy and the Ca2-sensitive indicator fura-2, as described else-
where.25 In brief, ﬁbroblasts from presenilin mutation–positive pa-
tients and unaffected controls (70%–90% conﬂuent) were grown
on uncoated glass-bottom dishes (MatTek) and were incubated
for 30–45 min with fura-2/AM 2.5–5.0 mM with Pluronic 0.01%–
0.05% (Molecular Probes). After washing twice and allowing 30–
60 min to complete ester hydrolysis, ﬁbroblasts were perfused
(1.6 ml/min) with 300 mOsm buffer (pH 7.4, at room tempera-
ture) containing 138 mM NaCl, 5 mM KCl, 10 mM HEPES, 1.2
mMMgCl2, 2.4mMCaCl2, 1.2mMNaH2PO4, and 10mMglucose.
The tip of the perfusion device was positioned at the edge of a
10-mm well that maintained a volume of 50–75 ml by suction.
Fibroblasts were illuminated using an invertedmicroscope (Nikon
TE2000E) with 340 nm and 380 nm light (Chroma) alternated
by a Lamda 103 ﬁlterwheel (Sutter Instruments), reﬂected by a
400-nm dichroic longpass ﬁlter, and were monitored at 510
nm. Images were visualized using an ORCA ER CCD camera40
(Hamamatsu Photonics) and were binned and stored for subse-
quent analysis (MetaFluor [Molecular Devices]). Estimated Ca2
concentration (EST [Ca2]i) was determined as described else-
where,25 with background correction, in vitro calibration, and the
dissociation constant of 224 nm.
Protein Alignments
Multiple sequence alignments were performed with the CLUS-
TALW algorithm and BOXSHADE program. In ﬁgure 1, identical
residues are indicated by the blackened background, and the con-
served residues are shown on the gray background. Protein se-
quences were obtained from GenBank. The accession numbers for
PSEN1 are as follows: NP_000012 (human), AAR97724 (dog),
NP_062036.2 (rat), NP_032969.1 (mouse), NP_989494.1 (chicken),
and CAB40386 (zebraﬁsh). The accession numbers for PSEN2 are
as follows: BC006365 (human), NM_174440 (bovine), NM_031087
(rat), BC010403 (mouse), NM_204302 (chicken), and BC065382
(zebraﬁsh).
Results
Genetic Studies
The PSEN1 and PSEN2 genes were evaluated for sequence
variations in the probands of 132 independent familieswith
FDC and 183 patients with IDC or possible FDC, whose
identiﬁcation has been described elsewhere.23 A single-nu-
cleotide variant (1539ArG) (GenBank accession number
L76517) in exon 10 of PSEN1 was detected in the index
patient of family A (ﬁg. 1A). The variant was predicted to
change a highly conserved aspartic acid at residue 333 to
glycine (D333G) (ﬁg. 1B and 1C).26,27 This change from a
negatively charged aspartic acid to an uncharged glycine
could be expected to signiﬁcantly impact the structure and
function of PSEN1.
A CrT transition at nucleotide 756 (GenBank accession
number NM_000447) was found in exon 5 of PSEN2 in
the index patients from families B and C (ﬁg. 1A). The
variant was predicted to substitute a highly conserved ser-
ine at residue 130 with a leucine (S130L) (ﬁg. 1B). Serine
is a polar hydrophilic amino acid, whereas leucine is a
nonpolar hydrophobic residue. A new StyI restriction site
was created by the variant and was used to independently
conﬁrm the presence of the alteration.
The PSEN1 and PSEN2 sequence variants were not de-
tected in 413 unaffected unrelated individuals, of whom
206were white and 207were AfricanAmerican.Haplotype
analysis of families B and C indicated that this sequence
variant did not originate from a common ancestor (data
not shown).
The coding sequences and intron/exon junctions of six
known FDC genes—LMNA, MYH7, TNNT2, SCN5A, CSRP3,
and PLN—were sequenced from DNA from the probands
of families A, B, and C. No mutations were identiﬁed.
Clinical Studies
Family A.—Family A is an African American family in
which the onset of DCM and heart failure ranged from
age 24 to 69 years (table 1 and ﬁg. 2). Mortality from pro-
gressive heart failure usually followed within a few years
of diagnosis. The index patient (II.4) presentedwith symp-
tomatic heart failure due to IDC at age 52 years. Family
member II.3 presented with IDC and heart failure at age
51 years, which progressed and required cardiac trans-
plantation at age 62 years. On the basis of these two
patients, a diagnosis of FDC was established. Subsequent
family evaluation revealed that three additional family
members (I.2, II.8, and III.2) had died of DCM and heart
failure before the family came to our attention. Inheri-
tance was consistent with an autosomal dominant pat-
tern. Extensive hospital records showed that family mem-
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Figure 3. Histological examination of LV myocardium from an affected member of family A and controls. Histological examination
was performed on LV myocardial tissue from the explanted heart taken at the time of cardiac transplantation of an affected member
(II.3) of family A, who carried the PSEN1 mutation. A, Regions of myocardial dropout and irregular ﬁbrosis, consistent with remote
ischemic damage (Gomori’s modiﬁed trichrome; 2#). B–D, Pleomorphic hyperchromatic myocardial nuclei. Panel B demonstrates the
diffuse nature of this change (20#). Panels C and D demonstrate rectangular boxcar nuclei (hematoxylin and eosin staining; 60#).
E, Control ventricular myocardium, from a patient with amyloid cardiomyopathy, that demonstrates birefringent amyloid deposits (Congo
Red under polarized light; 40#). F, Myocardium from subject II.3, in which no amyloid was observed (Congo Red under polarized light;
40#). G, Immunoperoxidase staining of control tissue from a patient with AD and congophilic amyloid angiopathy, which demonstrates
strong reactivity with the antioligomeric antibody (AHB0052) (40#). H, Ventricular myocardium from subject II.3, which demonstrated
no evidence of reactivity with AHB0052 (40#).
ber I.2 had received the diagnosis of heart failure and non-
ischemic DCM at age 69 years and with dementia at age
71 years. Both the DCM and dementia progressed and
resulted in repeated hospitalizations until the patient’s
death at age 78 years, in advanced heart failure. Hospital
records contained a medical diagnosis of “Alzheimer’s de-
mentia.” No autopsy was performed. Family member II.8
died at age 39 years of advanced heart failure despitemed-
ical therapy; an ejection fraction was 0.10, and coronary
angiography was normal. The endomyocardial biopsy sam-
ple was negative for iron or amyloid deposition (data not
shown). Family member III.2 presented at age 24 years in
advanced heart failure with an ejection fraction of 0.20
and an LV dimension, in diastole, of 75 mm. Coronary
angiography was normal. Death resulted at age 30 years
from advanced refractory heart failure despite fullmedical
therapy. Family member III.3 died of progressive heart fail-
ure at age 44 years. Coronary heart disease was excluded
by nuclear imaging, and the ejection fraction was 0.10,
with an LV dimension, in diastole, of 77mm. All clinically
affectedmembers of family A for whomDNAwas available
were positive for the PSEN1 mutation.
Histological examination of cardiac tissue from the ex-
planted heart of an affected family member (II.3) demon-
strated multiple abnormalities consistent with DCM (ﬁg.
3). Regions of replacement of normal myocardium with
variably dense ﬁbrous tissue were identiﬁed. No inﬂam-
mation was present in these areas; only rare macrophages
were identiﬁed. The myocardial cells contained variably
enlarged, hyperchromatic, and pleomorphic nuclei with
frequent rectangular forms (known as “boxcar nuclei”).
No intracellular or extracellular deposits suggestive of am-
yloid were identiﬁed with staining for Congo Red or with
immunoperoxidase stains for amyloid-b peptide, hyper-
phosphorylated tau, a-synuclein, or oligomerized peptide.
Family B.—Family B was a white family with onset of
cardiovascular disease at age 48–55 years (table 1 and ﬁg.
2). The index patient (III.5) presentedwith IDC and decom-
pensated heart failure requiring hospitalization, which sta-
bilized and improved with medical therapy. Shortly there-
after, family member III.8 received the diagnosis of IDC,
which established the diagnosis of FDC. Both carried the
PSEN2 mutation. On research screening, four additional
survivingmutation carriers were identiﬁed (ﬁg. 2 and table
1). One family member (III.7) had an anterior infarct pat-
tern on ECG, negative coronary angiography, and LV en-
largement without systolic dysfunction; two (III.3 and
III.9) had anterior infarct patterns on ECG but no prior
history of ischemic heart disease and negative results of
screening tests for myocardial ischemia. ECG abnormal-
ities13,24,28 and LV enlargement28 have been suggested as
early signs of FDC. One mutation-positive familymember
(III.2) had normal results on cardiovascular screening, sug-
gesting reduced penetrance, as has been observed else-
where in FDC.13 One obligate carrier from the second gen-
eration (II.3) had the onset of dementia at age 75 years
without evidence of cardiovascular disease.
Family C.—Family C was of white origin. Three siblings
(II.2, II.5, and II.7) received the diagnosis of DCM on the
basis of ventricular dilatation and systolic dysfunctionand
had the onset of cardiovascular disease between ages 36
and 45 years (table 1 and ﬁg. 2); they were found to have
the PSEN2 mutation. Two of the ﬁve mutation carriers
aged 135 years (I.1 and II.4) did not show evidence of
Figure 4. Histamine-induced alteration of intracellular calcium concentration ([Ca2]i) in cultured skin ﬁbroblasts derived from control
subjects and those with a PSEN1 or PSEN2 mutation. A, Representative experiment from cells loaded with fura-2/AM. A photomicrograph
from one dish of control cells is shown (inset). The baseline was recorded for 300 s before exposure to 100 mM histamine for 150 s.
Each tracing represents the measured [Ca2]i from a single ﬁbroblast. B, Baseline [Ca
2]i measured before the application of histamine.
Baseline [Ca2]i was higher in ﬁbroblasts cultured from patients with the PSEN1 or PSEN2 mutations than in ﬁbroblasts cultured from
control subjects. The data shown include the mean ( SEM) responses from control patient 1 (six dishes; 453 cells), control patient
2 (four dishes; 241 cells), control patient 3 (three dishes; 98 cells), a PSEN1 mutation carrier (eight dishes; 440 cells), and a PSEN2
mutation carrier (eight dishes; 561 cells). There was an average of 62 cells per dish, with a range of 21–92 cells. C, Maximal [Ca2]i
response to histamine. The histamine-induced [Ca2]i response was increased in ﬁbroblasts with the PSEN2 mutation compared with
those of three controls. The response from ﬁbroblasts with the PSEN1 mutation was different from one of three controls ( ).P ! .0001
The results shown are the peak responses in [Ca2]i to 100 mM histamine. D, Elapsed time to the maximal [Ca
2]i responses following
histamine application. No difference was observed between the ﬁbroblasts derived from control patients and those with a PSEN1 or
PSEN2 mutation. The elapsed time was measured in seconds from the histamine application to the maximal response of [Ca2]i. The
perfusion ﬂow rate was high compared with the dish volume; therefore, cells were exposed to 100 mM histamine in !3 s. E, Area under
the curve (AUC) of the histamine-induced increase in [Ca2]i. The total AUC of the histamine-induced increase in [Ca
2]i was higher in
ﬁbroblasts from patients with the PSEN1 and PSEN2 mutation than in ﬁbroblasts from control patients. F, AUC during the plateau phase
of the histamine-induced increase in [Ca2]i. The mean plateau phase [Ca
2]i response in ﬁbroblasts cultured from patients with the
PSEN1 or PSEN2 mutations was greater than the responses from ﬁbroblasts cultured from control patients. The AUC during the plateau
phase of the histamine application was measured from 390 to 450 s. A triple asterisk (***) indicates in three of three controlsP ! .0001
(Bonferroni/Dunn t test); a double asterisk (**) indicates in two of three controls.P ! .0001
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cardiovascular disease, suggesting reduced penetrance and/
or variable age at onset, as has been observed elsewhere
in FDC.13,28 None of the mutation carriers from the third
generation (all aged !35 years) showed evidence of DCM
or heart failure.
Fibroblast Calcium Studies
Previous studies have established that intracellular cal-
cium signaling is altered with AD-related presenilinmuta-
tions.29,30 Histamine-induced calcium signaling occurs in
both myoﬁbroblasts31 and skin ﬁbroblasts.32 We therefore
evaluated intracellular calcium signaling in cultured skin
ﬁbroblasts from PSEN1 and PSEN2 mutation carriers in
comparison with ﬁbroblasts from unaffected subjects (ﬁg.
4). Resting intracellular calcium concentrations were ele-
vated in cultured ﬁbroblasts from patients with PSEN1 or
PSEN2 mutations, as were histamine-stimulated maximal
calcium concentrations and the area under the curve, sug-
gesting that the identiﬁed presenilin mutations may have
functionally disrupted intracellular calcium signaling in
these cells.
Discussion
We identiﬁed a novel PSEN1 mutation in one family and
a single PSEN2 missense mutation in two families from a
large cohort of probands with FDC or IDC. Bothmutations
altered highly conserved amino acids, and neither was
observed in DNA samples from 413 unrelated unaffected
controls. Altered calcium signaling was observed in cul-
tured skin ﬁbroblasts derived from mutation carriers. The
mutations were present in all clinically affected subjects
and segregated with DCM and heart failure. The cardio-
vascular disease phenotype attributed to the PSEN1 mu-
tation in family A appeared to be fully penetrant and was
manifest as aggressive DCM and advanced heart failure
that usually resulted in the necessity of cardiac transplan-
tation or in death. A milder cardiovascular disease phe-
notype was associated with the PSEN2 mutation in fam-
ilies B and C, which did not predispose to lethality or the
need for cardiac transplantation, was less commonly asso-
ciated with heart failure, and was associated with a more
favorable response tomedical therapy. FDChas been shown
elsewhere to demonstrate widely variable clinical presen-
tations, penetrance, and age at onset associated with locus
and allelic heterogeneity.13 We conclude that these data
strongly suggest but do not prove that presenilin muta-
tions are causative of DCM and that additional studies
will be required to clarify the degree of cardiovascular risk
they incur.
Two cases of dementia were identiﬁed within the three
families. One subject (I.2 from family A) experienced
DCM and heart failure at age 69 years, followed by de-
mentia at age 71 years. No DNA was available from that
subject, precluding genetic testing to determine whether
that family member carried the PSEN1 mutation. The
second subject (II.3 from family B), an obligate carrier of
the PSEN2 mutation, had the onset of dementia at age
75 years. This PSEN2 mutation has been brieﬂy reported
in association with AD in a small kindred33 and is near
a different PSEN2 mutation associated with early-onset
familial AD.34 Thus, it is possible that the identiﬁed pre-
senilin mutations may have contributed to the dementia
observed in these subjects.
It remains to be determined whether the disease mech-
anisms suggested elsewhere to cause AD are relevant for
the DCM observed in our study families. The presenilins,
in concert with other proteins, form the g-secretase com-
plex (ﬁg. 1C) that acts on numerous protein substrates. A
notable type I protein substrate of the g-secretase complex
is the amyloid precursor protein (APP). Although rare, APP
mutations causing early-onset familial AD were the ﬁrst
identiﬁed genetic causes of AD.7 Not surprisingly, PSEN1
and PSEN2 mutations have been associated with disor-
dered proteolysis of APP.7 The result is an increased ra-
tio of the ﬁbrillar amyloid peptides Ab-42:Ab-40 and in-
creased amyloid deposition in the CNS.7–10 Interestingly,
amyloid deposition has been observed in tissues beyond
the CNS in patients with familial AD.35 Since the genes
for the presenilins19,20 and APP36 are expressed in the heart,
as is g-secretase activity,20 an APP-based pathogenesis of
DCM cannot be excluded. However, no evidence of am-
yloid-induced DCM was found by direct examination of
ventricular myocardium from the explanted heart of an
affected PSEN1 mutation carrier.
Considerable evidence suggests that disordered g-secre-
tase–dependent signaling pathways other than APP may
have caused DCM in these families. The presenilins in-
teract with 120 proteins10 that couple to diverse signaling
pathways, several of whichmay be relevant formyocardial
disease. For example, a key transcriptional regulator of
cardiac growth and development is the Notch protein fam-
ily.37 Phenotypes such as syndromic cardiovascular dis-
ease, congenital heart disease, valvular abnormalities, and
myocyte dysfunction have been associated with disor-
dered Notch,38 Notch activating ligand,39 and downstream
signaling such as Hey2.40 It was therefore of interest that
two PSEN2 mutation carriers had congenital cardiovas-
cular disease (ventricular septal defect and bicuspid aortic
valve) (data not shown).
It is also possible that the observed presenilin-associated
DCM is not related to g-secretase activity. For example, b-
catenin signaling is required for normal cardiac growth
and development,41 and PSEN1mutationshavebeen shown
to cause defective b-catenin signaling.42 The PSEN1 mu-
tation identiﬁed in family A was positioned in a large cy-
toplasmic loop between transmembrane domains six and
seven7,8 (ﬁg. 1C). This domain is essential for the associ-
ation of PSEN1 and b-catenin.43 It is possible that the mu-
tation in PSEN1 disrupted its interaction with b-catenin,
contributing to a cardiovascular disease phenotype. An-
other possibility also unrelated to g-secretase activity is
disordered calcium handling, which has been associated
1038 The American Journal of Human Genetics Volume 79 December 2006 www.ajhg.org
with genetic cardiomyopathy.15 Our cellular experiments
demonstrated that histamine-induced calcium signaling
was signiﬁcantly altered in skin ﬁbroblasts expressing
presenilin mutations. A similar pattern of calcium tran-
sients was observed in evoked heart papillary muscle from
PSEN2-knockout mice.44 Furthermore, alterations of cal-
cium signaling induced by presenilin mutations may be
reversed by calsenilin, a protein that associates with the
C terminus of both PSEN1 and PSEN2.30 The abnormal
calcium signaling that we identiﬁed in skin ﬁbroblasts
from presenilin mutation carriers supports a hypothesis
of disordered calcium handling as a possible diseasemech-
anism in these families.
In summary, we have identiﬁed two distinct presenilin
mutations among DCM-affected families and have linked
genetic defects of presenilins with myocardial disease. Ad-
ditional studies exploring presenilin-related disease path-
ways may lead to novel understandings of cardiovascular
disease.
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